You found a great company, then watched it double before you got round to buying.

Bamco Inc. NY bought a new stake in Guardant Health, Inc. (NASDAQ: GH) during the undefined quarter,

Callan Family Office LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ: GH) in the s

On August 24, 2026, Guardant Health Inc (GH) shares fell 4.4% to a current price of $163.18, reflect

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will ap

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

A Delaware federal judge finalized a ruling ordering Guardant Health (NASDAQ:GH) to pay over $245.2

Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million a

Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease,

Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision

Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FD

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

Empowered Funds LLC trimmed its holdings in Guardant Health, Inc. (NASDAQ: GH) by 81.3% during the u

Dimensional Fund Advisors LP lowered its position in Guardant Health, Inc. (NASDAQ: GH) by 40.4% in

On August 06, 2026, Guardant Health Inc (GH) shares fell 3.4% today, trading at $157.58. Over the pa

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight an

Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overw

Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price

Three of these watchlist stocks have already passed their earnings tests.

RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raise

Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and rais

TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pric

U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other g

Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Kar

AngloGold Ashanti plc (“AngloGold Ashanti”, “AGA”, the “Company” or the “Group”) sai

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Es

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pr

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overw

Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises th

Evercore ISI Group analyst Vijay Kumar maintains Guardant Health (NASDAQ:GH) with a Outperform an

B of A Securities analyst Michael Ryskin maintains Guardant Health (NASDAQ:GH) with a Buy and rai

Bernstein analyst Eve Burstein maintains Guardant Health (NASDAQ:GH) with a Outperform and raises

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pr

Bernstein analyst Eve Burstein reinstates Guardant Health (NASDAQ:GH) with a Outperform and annou

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises

RBC Capital analyst Dan Leonard initiates coverage on Guardant Health (NASDAQ:GH) with a Outperfo

Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEX

Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises